Welcome to the Next Generation Kinase Inhibitors Summit – the Future of Targeted Therapies
Kinase inhibitors have proven to be efficacious and approvable targets, fueling recent investment into this exciting space as their therapeutic targeting is explored beyond oncology. However, increasing resistance to existing programs and safety bottlenecks threaten further progress. The next wave of kinase targets depends on innovation.
Join the Next Generation Kinase Inhibitors Summit to connect with experts across discovery, R&D and clinical medicine to discuss how to accelerate the next generation of kinase inhibitor drugs to market, which display maximal therapeutic efficacy and durable clinical responses.
Exploit novel kinase biology such as histidine kinase, phosphatases and multi-kinases to optimize specificity, enhance durability & leverage the highest clinical impact with Tony Hunter, Anavo & Kurome Therapeutics
Navigate the cutting-edge platforms that are revolutionizing kinase profiling to accelerate target selection, accurately predict off-target effects and fast-track your kinase inhibitor drug development with Lewis Cantley, DeepCure & Kings College London
Reimagine drug design to optimize potency and penetrate the blood brain barrier to transform the use of kinase inhibitors in neurodegeneration & brain metastasis with Biogen, Inhibikase & Black Diamond
Utilize biomarkers to inform a personalized medicine approach, rationalize combination strategy and weaponize against resistance for more durable clinical responses with Genentech, AstraZeneca & Massachusetts Medical School
Weaponize the interaction of kinases in the tumor microenvironment by optimizing combination strategy to overcome resistance and yield higher clinical responses with TG Therapeutics, Onconova & AUM Biosciences